



## Management Team

**Rudolf Fahrig** **CEO** Belgian, responsible for business and science. Conception and design of in  
**Prevention of Chemoresistance and Clinical Studies of RP101**

**Klaus Kuhl** **CMO** Physician, long-time experience as Head of Clinical Pharmacology in two  
**Prevention of Chemoresistance** operating pharmaceutical companies.

**Jörg-Christian Heinich** **CSO** Biologist, preclinical development of the drugs of the second generation. Elucidation  
**Prevention of Chemoresistance** of the mechanism of action of RP101 and 2nd generation substances.

**Torsten Fiedig** **COO** CFO Computer Scientist, responsible for finances, marketing and organisation.  
**Prevention of Chemoresistance**

**Andreas Dörner** **Director** Chemist, long-time experience in chemical syntheses. Preparation of drug master  
**Prevention of Chemoresistance** batches and EMA approvals.